What is Chardan Capital's Forecast for LXEO FY2025 Earnings?

Key Points

• Chardan Capital has increased its FY2025 earnings per share forecast for Lexeo Therapeutics from ($2.98) to ($1.99), maintaining a "Buy" rating with a target price of $15.00.
• Lexeo Therapeutics reported earnings of ($0.60) per share in its last quarterly announcement, exceeding projections of ($0.64).
• Despite varying price targets from different analysts, the average consensus rating for Lexeo Therapeutics remains a "Buy" with an estimated price target of $15.33.

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Analysts at Chardan Capital raised their FY2025 earnings per share (EPS) estimates for Lexeo Therapeutics in a research note issued to investors on Monday, August 18th. Chardan Capital analyst G. Livshits now forecasts that the company will post earnings per share of ($1.99) for the year, up from their prior estimate of ($2.98). Chardan Capital currently has a "Buy" rating and a $15.00 target price on the stock. The consensus estimate for Lexeo Therapeutics' current full-year earnings is ($3.14) per share.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($0.60) earnings per share for the quarter, beating analysts' consensus estimates of ($0.64) by $0.04.

Other equities analysts have also recently issued research reports about the company. JPMorgan Chase & Co. decreased their price target on Lexeo Therapeutics from $16.00 to $10.00 and set an "overweight" rating on the stock in a report on Friday, May 30th. Oppenheimer assumed coverage on Lexeo Therapeutics in a report on Thursday, July 31st. They set an "outperform" rating and a $20.00 target price on the stock. Finally, HC Wainwright dropped their price target on Lexeo Therapeutics from $15.00 to $9.00 and set a "buy" rating on the stock in a research report on Friday, August 15th. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $15.33.

Lexeo Therapeutics Stock Up 0.4%

Lexeo Therapeutics stock opened at $4.80 on Thursday. The business's 50-day simple moving average is $4.34 and its 200 day simple moving average is $3.69. The stock has a market cap of $159.36 million, a price-to-earnings ratio of -1.47 and a beta of 1.36. Lexeo Therapeutics has a 12-month low of $1.45 and a 12-month high of $12.76.

Institutional Investors Weigh In On Lexeo Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Millennium Management LLC raised its position in Lexeo Therapeutics by 282.5% in the 4th quarter. Millennium Management LLC now owns 141,951 shares of the company's stock valued at $934,000 after buying an additional 104,837 shares during the last quarter. BNP Paribas Financial Markets raised its position in Lexeo Therapeutics by 523.1% in the 4th quarter. BNP Paribas Financial Markets now owns 34,527 shares of the company's stock valued at $227,000 after buying an additional 28,986 shares during the last quarter. Marshall Wace LLP acquired a new stake in Lexeo Therapeutics in the 4th quarter valued at approximately $117,000. Wellington Management Group LLP raised its position in Lexeo Therapeutics by 48.3% in the 4th quarter. Wellington Management Group LLP now owns 76,981 shares of the company's stock valued at $507,000 after buying an additional 25,089 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Lexeo Therapeutics by 30.1% in the 4th quarter. JPMorgan Chase & Co. now owns 13,371 shares of the company's stock valued at $88,000 after buying an additional 3,093 shares during the last quarter. Institutional investors and hedge funds own 60.67% of the company's stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.